Get the Stockscreener App
2.88
1.71%
-0.05
Pre-market:
2.86
-0.02
-0.69%
Spero Therapeutics Inc stock is traded at $2.88, with a volume of 1.01M.
It is down -1.71% in the last 24 hours and up +313.61% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.93
Open:
$2.97
24h Volume:
1.01M
Relative Volume:
0.26
Market Cap:
$156.55M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
288.00
EPS:
0.01
Net Cash Flow:
$28.98M
1W Performance:
-0.69%
1M Performance:
+313.61%
6M Performance:
+207.20%
1Y Performance:
+116.54%
1-Day Range:
$2.81
$2.97
1-Week Range:
$2.81
$3.02
52-Week Range:
$0.5052
$3.06
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.88 | 156.55M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha
Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN
Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN
Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey
Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa
Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN
Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter
Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail
GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com
Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN
Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
GSK, Spero stop UTI drug trial after early success - Reuters
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India
Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com Nigeria
Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia
Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance
Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Advances Phase 3 Trial With Strong Cash Position, Welcomes New CEO - Stock Titan
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times
Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune
SPROSpero Therapeuti Latest Stock News & Market Updates - Stock Titan
Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spero Therapeutics Inc Stock (SPRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rajavelu Esther | CFO & CBO |
Feb 05 '25 |
Sale |
0.78 |
20,689 |
16,137 |
724,720 |
| Shukla Sath | CEO & President |
Feb 05 '25 |
Sale |
0.78 |
155,333 |
121,160 |
1,736,883 |
| Mahadevia Ankit | Director |
Feb 05 '25 |
Sale |
0.78 |
69,219 |
53,991 |
689,866 |
| Rajavelu Esther | CFO & CBO |
Nov 07 '24 |
Sale |
1.31 |
23,351 |
30,590 |
396,515 |
| Rajavelu Esther | CFO & CBO |
Nov 08 '24 |
Sale |
1.30 |
17,245 |
22,418 |
379,270 |
| Mahadevia Ankit | Director |
Aug 27 '24 |
Sale |
1.35 |
5,912 |
7,981 |
759,085 |
| Keutzer Timothy | Chief Operating Officer |
Aug 27 '24 |
Sale |
1.35 |
2,213 |
2,988 |
531,837 |
| Shukla Sath | CEO & President |
Aug 27 '24 |
Sale |
1.35 |
2,757 |
3,722 |
1,140,809 |
| Shukla Sath | CEO and President |
Aug 05 '24 |
Sale |
1.31 |
17,641 |
23,110 |
1,143,566 |
| Shukla Sath | CEO and President |
Aug 02 '24 |
Sale |
1.32 |
14,800 |
19,536 |
1,161,207 |
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):